The thrombophilic state in acute promyelocytic leukemia

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 2, 1999, Pages 209-214

  Tallman, Martin S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Coagulopathy; Disseminated intravascular coagulation (DIC); Hemorrhage

Indexed keywords

ARSENIC TRIOXIDE; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; BLEEDING TENDENCY; CELL INTERACTION; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFECT; FIBRINOLYSIS; HUMAN; LEUKEMIA CELL; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTHROMBIN TIME; REVIEW; THROMBOCYTOPENIA; THROMBOPHILIA;

EID: 0032934735     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994922     Document Type: Review

References (72)

1. Larson R, Kondo K, Vardiman JW, et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984;76:827-841
2. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990;347:558-561
3. Alcalay M, Zangrilli D, Dandolf PP, et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor α locus. Proc Natl Acad Sci USA 1991;88: 1977-1981
4. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79:543-553
5. Gralnick HR, Bagley J, Abrell E. Heparin treatment for the hemorrhagic diathesis of acute promyelocyte leukemia. Am J Med 1972;52:167-174
6. Jones ME, Saleem A. Acute promyelocytic leukemia: A review of the literature. Am J Med 1978;65:673-677
7. Cordonnier C, Vernant JP, Brun B, et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985;55:18-23
8. Kantarjian HM, Keating MJ, Walters RS, et al. Acute promyelocytic leukemia: The MD Anderson Hospital experience. Am J Med 1986;80:789-794
9. Cunningham I, Gee TS, Reich LM, et al. Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital. Blood 1989;72:1116-1121
10. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and antihemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study of 268 consecutive patients. Blood 1990;75:2112-2117
11. Head D, Kopecky KJ, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995;86:1717-1728
12. Goldberg MA, Ginsburg D, Mayer RJ, et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 1987;69: 187-191
13. Bennett JM, Young ML, Andersen JW, et al. Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group Experience. Cancer 1997;80:2205-2209
14. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-572
15. Castaigne S, Chomienne C, Daniel M-T, et al. All-trans retinoic acid as differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704-1709
16. Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans- retinoic acid). N Engl J Med 1991;374:1385-1393
17. Chen ZX, Xue YQ, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid - treated acute promyelocytic leukemia patients. Blood 1991;78:1413-1419
18. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995;85:1202-1206
19. Ohno R, Yoshida H, Futakami H, et al. Multi-institutional study of all-trans retinoic acid as differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 1993;7:1722-1727
20. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial. Blood 1993; 82:3241-3249
21. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337:1021-1028
22. Gralnick HR, Sultan, C. Acute promyelocytic leukemia: Hemorrhagic manifestations and morphologic criteria. Br J Haematol 1975;29:373-376
23. Groopman J, Ellman L. Acute promyelocytic leukemia. Am J Hematol 1979;7:395-408
24. Collins AJ, Bloomfield CD, Peterson BA, McKenna RW, Edson R. Acute promyelocytic leukemia: Management of the coagulopathy during daunorubicin-prednisone remission induction. Arch Intern Med 1978;138:1677-1680
25. Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukemia: Fibrinolysis due to u-PA rather than defibrination. Br J Haematol 1989;71:511-517
26. Bennett M, Parker AC, Ludlam CA. Platelet and fibrinogen survival in acute promyelocytic leukemia. Br Med J 1976;2: 565-569
27. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1-8
28. Bauer KA, Conway EM, Bach R, et al. Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res 1989;50: 425-430
29. Andoh K, Sadakata H, Uchiyama T, et al. One-stage method for assay of tissue factor activity of leukemic cells with special reference to disseminated intravascular coagulation. Am J Clin Pathol 1990;93:679-684
30. Kubota T, Andoh T, Sadakata H, Tanaka H, Kobayushi N. Tissue factor released from leukemic cells. Thromb Haemost 1991; 65:59-63
31. Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: A factor X activating procoagulant from malignant tissue. Thomb Res 1975;6:127-137
32. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant A: A cystine proteinase from malignant tissue. Biochemistry 1985;24:5558-5567
33. Donati MB, Falanga A, Consonni R, et al. Cancer procoagulant in acute nonlymphoid leukemia: Relationship of enzyme detection to disease activity. Thromb Haemost 1990;64:11-16
34. Bevilacqua MP, Pober JS, Majeau GR, Lotran RS, Gimbrone MA. Interleukin-1 expression activity of procoagulant activity in human vascular endothelia cells. J Exp Med 1984;160: 618-623
35. Bevilacqua MP, Pober JS, Majeau GR, et al. Recombinant human tissue necrosis factor induces procoagulant activity in cultured human vascular endothelium. Characterization and comparison with interleukin-1. Proc Natl Acad Sci USA 1986;83: 4533-4537
36. Nawroth PP, Handley D, Esmon CT, Stern DM. Interleukin-1 induces cell surface anticoagulant activity. Proc Natl Acad Sci USA 1986;83:3460-3464
37. Nawroth PP, Stern MD. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163: 740-745
38. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity and promotes monocyte migration. J Exp Med 1990;172:1535-1545
39. Cozzolino F, Torcia M, Miliani A, et al. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am J Med 1988;84:240- 250
40. Emeis JJ, Kooistra T. Interleukin-1 and lipopolysaccharides induce an inhibitor of plasminogen activator in vivo and in human cultured endothelial cells. J Exp Med 1986;163: 1260-1266
41. Nachman RL, Hajjar KA, Silverstein RL, Dinarello CA. Interleukin-1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1996;163:1595-1600
42. Miyauchi S, Morohama T, Kyoizumi S, et al. Malignant tumor cell lines produce interleukin-1-like factor in vivo. In Vitro Cell Dev Biol 1988;24:753-758
43. Noguchi M, Sakai T, Kisiel W. Identification and partial purification of novel tumor-derived protein that induces tissue factor in cultured human endothelial cells. Biochem Biophys Res Commun 1989;160:222-227
44. Chan TK, Chan GT, Chan V. Hypofibrinogenemia due to increased fibrinolysis in two patients with acute promyelocytic leukemia. Aust NZ J Med 1984;14:245-249
45. Sterrenberg L, Haak HL, Brommer EJP, Nieuwenhuizen W. Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Hämostasis 1985;15: 126-133
46. Schwartz BS, Williams EC, Conlan MG, Mosher DF. Epsilon- aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency. Ann Intern Med 1986;105:873-877
47. Velasco F, Torres A, Andres P, Martinez F, Gomez P. Changes in plasma levels of protease and fibrinolytic inhibitors induced by treatment of acute promyelocytic leukemia. Thromb Haemost 1984;52:81-84
48. Wilson EL, Jacobs P, Dowdle EB. The secretion of plasminogen activators by human myeloid leukemia cells in vitro. Blood 1983;61:568-578
49. Sakata Y, Murakami T, Noro A, Mori K, Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991;77:1949-1957
50. 2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci USA 1980;77:2533-2536
51. Chang KS, Wang G, Freireich EJ, et al. Specific expression of the annexin VIII gene in acute promyelocytic leukemia. Blood 1992;79:1802-1810
52. Dombret H, Scrobohaci ML, Zini JM, et al. Coagulation disorders associated with acute promyelocytic leukemia: Corrective effect of all-trans retinoic acid treatment. Leukemia 1993; 7:2-9
53. 3 leukemia. Blood 1992; 79:534-535
54. Escudier SM, Kantarjian HM, Estey EH. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leukemia Lymphoma 1996;20:435-439
55. Hashimoto S, Koike T, Tatewaki W, et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy as prophylaxis of hemorrhage. Leukemia 1994;8:1113-1115
56. Ishii H, Horie S, Kizaki K, Kazama M. Retinoic acid counteracts both the downregulalion of thrombomodulin and the induction of tissue factor in cultured human endothelial cells exposed to tumor necrosis factor. Blood 1992;80:2556-2562
57. Rickles FR, Hair G, Schmeizel M, Kwaan H, Tallman M. All- trans-retinoic (ATRA) inhibits the expression of tissue factor in human progranulocytic. Thromb Haemost 1993;69:107(Abstr)
58. Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995;86:1072-1081
59. De Stefano V, Teofili L, Sica S, et al. Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood 1995;86:3535-3541
60. Medh R, Santell L, Levin EG. Stimulation of tissue plasminogen activator production by retinoic acid: Synergistic effect on protein kinase c-mediated activation. Blood 1992;80:981-987
61. Lansink M, Kooistra T. Stimulation of tissue-type plasminogen activator expression by retinoic acid in human endothelial cells retinoic acid receptor β2 induction. Blood 1996;88:531-541
62. Falanga A, Consom R, Marchetti M, et al. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans retinoic acid. Leukemia 1994;8:156-159
63. Tallman MS, Lefebvre P, Cohen I, et al. Procoagulant, profibrinolytic and proinflammatory mediators in patients with previously untreated acute promyelocytic leukemia (APL). Blood 1995;86:675(Abstr)
64. Fenaux P, Chastang C, Sanz M, et al. ATRA followed by chemotherapy (CT) vs ATRA plus CT and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia (APL): First interim results of APL93 trial. Blood 1997;90:533(Abstr)
65. Burnett AK, Goldstone AH, Gray RG, Uheatley K. All trans retinoic acid given concurrently with induction chemotherapy improves the outcome of APL: Results of the UK MRC ATRA trial. Blood 1997;90:1474(Abstr)
66. Avvisati G, Personal communication
67. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol 1998; 16:78-85
68. Sanz MA, Martin G, Gonzalez M, et al. High molecular remission (MR) rate and low toxicity with a modified AIDA protocol omitting cytarabine and etoposide from treatment of newly diagnosed PML/RARα - Positive acute promyelocytic leukemia (APL). Blood 1998;92:403a(Abstr)
69. Di Bona E, Castaman G, Avvisati G, et al. Hemostasis related early morbidity and mortality during remission induction treatment with or without all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL). Blood 1997;90:1478(Abstr)
70. 3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-3353
71. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360
72. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-1348